Keywords: Airway, blood pressure bronchodilation neuropeptides nitric oxide pituitary adenylate cyclase-activating peptide vasoactive intestinal peptide Received: November 16 1998 Accepted after revision April 17 1999 Two endogenous forms of pituitary adenylate cyclaseactivating peptide (PACAP) are known; PACAP 1-27 and PACAP 1-38, where PACAP 1-27 constitutes the N-terminal portion of PACAP 1-38. Both forms of PACAP are amidated and share some of their biochemical properties with peptides such as vasoactive intestinal peptide (VIP), peptide histidine isoleucide, helospectrin and helodermin [1] . PACAP 1-27 and 1-38 were originally isolated from ovine hypothalami, and they increase intracellular cyclic adenosine monophosphate (cAMP) in pituitary cells a thousand-fold more potently than VIP [2, 3] . PACAP 1-27 and 1-38 display several biological activities that may be relevant to the treatment of obstructive airway disease such as asthma and chronic obstructive pulmonary disease. These activities include inhibition of airway [4±6] and vascular smooth muscle tone [7] , as well as modulation of inflammatory cell activity [8±14] .
This article reviews data suggesting that PACAP 1-38, or synthetic analogues of PACAP 1-27, may be useful as bronchodilators with potential anti-inflammatory properties. These molecules appear superior to VIP in terms of sustained bronchodilatory effect combined with lack of cardiovascular side effects in vivo. They may constitute an PACAP receptors and mechanism of action in airway smooth muscle
The specific receptor subtypes for PACAP 1-27 and 1-38 in airway smooth muscle are not yet characterized in detail. However, it is known that PACAP 1-27 and PACAP 1-38 have high affinity binding sites in the rat lung [16± 18] , probably including neuromuscular sites pre-and post-junctionally in bronchial smooth muscle, as indicated by functional studies in guinea pig airways in vitro and in vivo [5, 19±21] . At these lung binding sites, the affinity for PACAP 1-27, 1-38 and VIP is fairly similar, which is compatible with the presence PACAP type II receptors [16±18, 22±25] . Transcripts from human lung tissue indicate the presence of PACAP type II receptors as well [26] . More extensive studies on this type of receptor binding are lacking, however. In the guinea pig trachea in vitro, PACAP-induced smooth muscle relaxation is probably caused by cAMP-mediated activation of Ca ++ -dependent K + -channels [19, 27, 28] . At present, it is not clear whether additional, intracellular mechanisms, such as the signal transduction via the glutamyl transpeptidase (GTP-ase) protein Ras and the cytoplasmic mitogen activated protein kinase Raf, contribute to the effect of the PACAPs in airway smooth muscle [29] .
PACAP and airway smooth muscle
In the guinea pig trachea in vitro, PACAP 1-38 inhibits smooth muscle tone induced by acetylcholine, histamine or metacholine [4, 28, 30, 31] ( fig. 1 ) with markedly longer duration of action than that of PACAP 1-27 or VIP, parallelled by a more sustained increase in cAMP by PACAP 1-38 [27, 31] . VIP is, however, slightly more potent than PACAP 1-27 or 1-38 in relaxing the guinea pig trachea in vitro [4, 30, 32] . In contrast, PACAP 1-38 at least, is more potent than VIP in causing an increase in cAMP in this type of airway smooth muscle [32] . Perhaps of greater relevance to human airways. PACAP 1-27 inhibits smooth muscle tone in primate bronchi precontracted by carbachol in vitro [5] (fig. 2) . In this airway model, PACAP 1-27 is equipotent to the clinically utilised b 2 -adrenoceptor agonist salbutamol.
In guinea pigs in vivo, inhalation of PACAP 1-27 and 1-38 [5, 33] causes significant inhibition of histamineinduced bronchoconstriction (figs. 3 and 4a). This effect of inhaled PACAP 1-38 is markedly more sustained than that of PACAP 1-27 or VIP ( fig. 4b ), although the potency of these peptides appears to be nearly the same [20] . Intravenous administration of PACAP 1-27 and 1-38 inhibits carbachol-or histamine-induced bronchoconstriction and these effects are dose-dependent [5, 20, 33] (figs. 5 and 6). PACAP 1-38 given intravenously is also longer acting than PACAP 1-27 [33] . Interestingly, intravenous administration of PACAP 1-27 virtually abolishes bronchoconstriction caused by a near-maximally effective dose of allergen in sensitized guinea pigs [5] (fig. 7 ). 
PACAP and endopeptidases in airway smooth muscle
In the guinea pig trachea in vitro, phosphoramidon, a selective inhibitor of neutral endopeptidase (NEP) potentiates the inhibitory effect on tone induced by PACAP 1-27 [5, 6] (fig. 8 ). This effect of phosphoramidon is epithelium-dependent, indicating the involvement of epithelial NEP [32] . In contrast, a mixture of protease inhibitors including phosphoramidon, does not significantly potentiate the effect of PACAP 1-38 the same type of airway preparation [30] . However, phosphoramidon potentiates the cAMP response to PACAP 1-38 but not to PACAP 1-27 in human airway epithelial-like, adenocarcinoma cells in vitro [23] (fig. 9) . Possibly, the referred discrepancy can be explained by the fact that BHOGAL et al. [30] utilised a "cocktail" of various protease-inhibitors, each of which may either potentiate or inhibit the end point signal, resulting in a "zero" net outcome.
In guinea pigs in vivo, NEP inhibition with phosphoramidon significantly potentiates the bronchodilator effect of PACAP 1-38 given intravenously [33] , supporting a role of NEP in controlling airway effects of PACAP 1-38. In this context, there is no information available, to the authors' knowledge, on NEP and PACAP 1-27 in vivo.
PACAP analogues and airway smooth muscle
To extend the duration of its inhibitory action on airway smooth muscle tone, two novel structural analogues of PACAP 1-27 have been developed [6, 34, 35] . The two analogue molecules were produced by replacing key amino acids ( fig. 10 ), resulting in the M and BM type of PACAP analogue. Recent data show that both of these peptide analogues cause a more sustained inhibition of smooth muscle tone in the guinea pig trachea in vitro than does the original PACAP 1-27 [6, 35] . min -1 , 15 min) versus the peak increase in total pulmonary resistance (RL; cmH 2 O . mL -1 . s -1 ) caused by inhaled histamine aerosol (m; 10 mM, 5 breaths) or infusion of carbachol intravenously (J: 0.1 mM, 0.5 mL) in anesthetized guinea-pigs in vivo. The RL responses to histamine and carbachol after infusion of the vehicle (phosphate buffered saline) are also presented (u, n). Data are meanSEM (n=3±4).
(Reproduced with permission from [20] ). action in primate bronchi in vitro [6] (fig. 13 ). The time to full onset of action is~1 h for both PACAP analogues in vitro (figs. 11 and 12). Interestingly, both these analogues maintain their full effect throughout the 5 h of observation in vitro. In contrast to the effect of the original PACAP 1-27, the effect of the M and BM type of PACAP analogue is not potentiated by NEP inhibition with phosphoramidon [6, 35] (figs. 8 and 14) . Thus, the sustained action of the PACAP analogues may at least in part be due to a reduced susceptibility to NEP.
In guinea pigs in vivo, intratracheal administration of the BM type of PACAP analogue decreases acetylcholine airway responsiveness significantly [36] . The onset of action is slow, requiring 4 h to produce a significant inhibitory effect on muscarinic responsiveness ( fig. 15 ). However this protective effect is not diminished throughout 5 h of observation.
PACAP and inflammatory cells

PACAP and airway inflammation
At present, it is not known whether either PACAP 1-27 or 1-38 exert beneficial effects on airway inflammation in vivo. However, there is data on the effect of PACAP 1-27 and 1-38 on isolated inflammatory cells.
PACAP and lymphocytes
PACAP 1-38 given in nanomolar concentrations inhibits the spontaneous mobility of rat lymphocytes in vitro, although this effect is dependent upon the activation state of protein kinase C [10] . Costimulation with the cAMPelevating agent forskolin inhibits chemotaxis of lymphocytes more potently than does PACAP 1-38 alone [8, 10] . A VIP receptor antagonist attenuates the referred effects in rat lymphocytes, indicating the involvement of PACAP type II receptors [10] . In humans, the PACAP type II receptor is predominant in peripheral B-lymphocytes, whereas the PACAP type I receptor is predominant in several human T-lymphocyte cell lines, as demonstrated by detection of receptor messenger ribonucleic acid (mRNA) for these receptors [37] . However, the expression of PACAP type II receptors is probably dependent upon the activation of lymphocytes [11] . PACAP 1-38 attenuates the production of the proinflammatory cytokine, interleukin (IL)-2 in murine Tlymphocytes in vitro [14] . This effect is mimicked by VIP and the cAMP-elevating agent forskolin. For VIP, this effect involves an inhibited transcription process via a cAMP-dependent transcription factor (nuclear factor of activated T-lymphocytes (NFAT)) as well as destabilization of IL-2 mRNA. However, in addition to its direct effect on IL-2, PACAP 1-38 also reduces the production of the anti-inflammatory cytokine IL-10, in murine Tlymphocytes [13] . This latter event occurs through the inhibition of transcription alone.
PACAP and granulocytes
There are no published data, to the authors' knowledge, on the effect of PACAP 1-27 or 1-38 on isolated granulocytes, either for eosinophils or for neutrophils. However, there is data suggestive of PACAP 1-27 acting on granulocytes. PACAP 1-27 given in micromolar concentrations attenuates the release of thromboxane B 2 caused by leukotriene D 4 in guinea pig lung strips in vitro [32] . This thromboxane may originate from granulocytes or thrombocytes.
PACAP and macrophages
PACAP 1-38 increases both adherence and mobility of isolated rat macrophages when given in nanomolar concentrations in vitro. These effects are dependent upon the activation state of protein kinase C [10] . The peptide is Amino acid sequence 1 5 10 H-His-Ser-Asp-Gly-Ile-Phe-Thr-Asp-Ser-Tyr-Ser-Arg-Tyr-Arg-Lys -Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu-Ala-Ala-Val-Leu-NH 2 H-His-Ser-Asp-Gly-Ile-Phe-Thr-Asp-Ser-Tyr-Ser-Arg-Tyr-Arg-Arg-Gln-Leu-Ala-Val-Arg-Arg-Tyr-Leu-Ala-Ala-Val-Leu-Gly-Lys-Arg-NH 2 H-His-Ser-Asp-Gly-Ile-Phe-Thr-Asp-Ser-Tyr-Ser-Arg-Tyr-Arg-Arg-Gln-Leu-Ala-Val-Arg-Arg-Tyr-Leu-Ala-Ala-Val- Leu chemotactic per se for rat macrophages, and it counteracts the inhibitory effect of forskolin on macrophage chemotaxis [10] . The cytotoxic action of macrophages may be increased by PACAP 1-38, because it triggers superoxide anion production with higher potency than VIP in human monocytes [38] . Both PACAP 1-27 and 1-38 enhance phagocytosis in mouse macrophages in vitro, and they do this more potently than VIP, particularly PACAP 1-38 [12] . PACAP 1-38 also stimulates phagocytosis in rat macrophages in vitro, parallelled by a significant increase in cAMP, via a pathway independent of protein kinase C [9] . The role of cAMP as a second messenger is also supported by the associated increase in cAMP and superoxide production after stimulation with PACAP 1-38 in human monocytes [38] . It is likely that PACAP type I receptors mediate the effects on macrophages, because a PACAP type II receptor antagonist does not affect chemotaxis or phagocytosis induced by PACAP 1-38 [9, 10] .
PACAP and mast cells
There are no functional studies on PACAP 1-27 or 1-38 in isolated mast cells, to the authors' knowledge, but mRNA for PACAP type II receptors has been detected in a murine mast cell line [37] . The observation that a histamine antagonist inhibits plasma extravasation caused by PACAP 1-38 in rat skin indicates that mast cells may mediate effects of PACAPs by releasing histamine [39] . Another supporting observation is that PACAP 1-38 releases histamine from rat peritoneal cells [40] . VIP, which acts via PACAP type II receptors (equipotently to the PACAPs), releases histamine from mast cells, including mast cells in human skin [41, 42] . Thus, it is possible that at least PACAP 1-38 exerts actions on mast cells or basophils, although there is no direct evidence for this at present.
PACAP and the cardiovascular system
PACAP and vascular smooth muscle
In vitro, PACAP 1-38 inhibits smooth muscle tone in the human pulmonary artery [6] . This effect is endotheliumand nitric oxide-dependent, which indicates a mechanism different from that of VIP ( fig. 16 ). In intact human artery in vitro, the potency of PACAP 1-38 is fairly similar to that of VIP in causing smooth muscle relaxation. Similarly, PACAP 1-38 relaxes the guinea pig pulmonary artery in vitro, but there is conflicting data on whether this relaxation is endothelium-dependent [4, 7, 43] . The rat mesenteric artery in vitro is also relaxed by PACAP 1-38, which is slightly more potent than PACAP 1-27 or VIP [16] . PACAP 1-38 given as an intravenous bolus also causes significant vasodilation in human subjects [44] . PACAP type II receptors probably mediate the effects on vascular smooth muscle, as indicated by the similar affinity for PACAP 1-27 and 1-38 and VIP in the rat aorta, the femoral and iliac arteries and veins [16, 45] .
PACAP and plasma extravasation
In high doses, PACAP 1-38 per se increases plasma extravasation more potently than PACAP 1-27 or VIP but slightly less potently than does substance P (SP) in rat skin in vivo [40] . However, in low doses, PACAP 1-38 does not cause plasma extravasation per se, but it does potentiate SP-induced extravasation in rabbit skin in vivo [48] . 
PACAP and the heart
Cultured neonatal rat myocardiocytes respond to PACAP 1-27 and 1-38 (but not to VIP) by increasing the intracellular level of cAMP and the secretion of atrial natriuretic peptide [47] , suggesting involvement of PACAP type I receptors. In support of this observation, PACAP 1-27 and 1-38 but not VIP increase myocardial inotropy in the neonatal pig heart in vitro [48, 49] . PACAP 1-27 is more potent than PACAP 1-38 in this model, approaching the potency of isoproterenol. PACAP 1-38 also increases right ventricular inotropy in the dog heart in vivo [50] . In the guinea pig ventricular strip in vitro, however, the inotropy is not affected by either PACAP 1-27 or 1-38, and chronotropy is decreased in the guinea pig atrium in vitro [51] . Similarly, inotropy is decreased in the denervated dog heart in situ and in the perfused dog heart in vitro while chronotropy is either increased or decreased by PACAP 1-38, depending on the dose [52, 53] . The increase in chronotropy that is caused by PACAP 1-38 may be due to a direct effect on sinus rate [53] . In contrast, VIP has no effect on chronotropy [51] and, therefore, PACAP type I receptors are probably involved in this response. Data showing a similar vasodilator activity of PACAP 1-27 and 1-38 and VIP suggests the presence of PACAP type II receptors in porcine coronary arteries [16, 49] .
In contrast to the effects on isolated hearts or heart cells, PACAP 1-38 has no effect on heart rate in human subjects when given as a slow intravenous infusion at a dose that increases endogenous arginine vasopressin [54] . Also, PACAP 1-27 causes less effect on heart rate than does the clinically utilized b 2 -adrenoceptor agonist salbutamol, during slow intravenous infusion at doses causing bronchodilation in guinea pigs in vivo [5] . Inhalation of PACAP 1-38 does not have negative effects on heart rate when given in doses causing bronchodilation in guinea pigs in vivo [20] . However, when given as an intravenous bolus, PACAP 1-38 and 1-27 do affect heart rate; in dogs in vivo, PACAP 1-27 causes a dose-dependent increase in heart rate but it is not known how the doses given relate to doses required for bronchodilation [55] . Under the same conditions, PACAP 1-38 causes only a minor increase in heart rate, and it is unclear whether this effect is due to a reflex caused by hypotension [55] . In the cat in vivo, a bolus injection of PACAP 1-38 increases heart rate [50] .
PACAP and blood pressure
When given as a slow intravenous infusion, in a dose that increases endogenous arginine vasopressin, PACAP 1-38 has virtually no effect on systemic blood pressure in human subjects [54] . Similarly, inhaled PACAP 1-38 does not decrease blood pressure, when given in doses causing bronchodilation in guinea pigs in vivo [20] . However, when given as an intravenous bolus, both PACAP 1-27 and 1-38 do cause systemic hypotension in rats in vivo [45] . Interestingly, in this rat model, PACAP 1-27 is less potent than PACAP 1-38, which is less potent than VIP. In dogs in vivo, PACAP 1-27 and 1-38 are clearly less potent than VIP in causing systemic hypotension when given as an intravenous bolus [55] . In dogs, the response is biphasic; an initial decreasing effect is followed by a moderate and more sustained increasing effect on systemic blood pressure [56] . Both PACAP 1-27 and 1-38 produce a moderate biphasic effect on systemic blood pressure in the cat in vivo, but PACAP 1-27 is the most potent [48, 50] . In contrast, VIP causes hypotension only in cats. The pressor effect of PACAP 1-27 or 1-38 on systemic blood pressure is mediated through catecholamines in cats and dogs, acting on a-adrenergic receptors in cats [48, 50] . PACAP 1-38 also increases the spinal sympathetic neural outflow in rats [57] . In cats in vivo, PACAP 1-27 and 1-38 either increase or decrease pulmonary artery pressure whereas VIP only decreases pulmonary artery pressure [48, 50] .
Conclusions
Pituitary adenylate cyclase-activating peptide-related molecules potently inhibit airway smooth muscle tone in several species both in vitro and in vivo. Pituitary adenylate cyclase-activating peptide 1-38 is clearly superior to vasoactive intestinal peptide after inhalation in vivo in terms of causing sustained bronchodilation without cardiovascular side effects. Pituitary adenylate cyclase-activating peptide 1-27 or 1-38 also inhibit chemotaxis and cytokine production of lymphocytes and may modulate the activity of macrophages and mast cells in vitro. Additional studies on human cells are required to determine whether pituitary adenylate cyclase-activating peptide-related molecules inhibit tone in bronchial smooth muscle and activity of inflammatory cells before these molecules should be tested for treatment of obstructive airways disease.
